comparemela.com

Latest Breaking News On - Contact lens discomfort - Page 2 : comparemela.com

Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company s Investigational Treatment for Contact Lens Discomfort

Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company’s Investigational Treatment for Contact Lens Discomfort Significant improvement in multiple measures of Meibomian gland secretion and associated improvements in contact lens wear time TEL AVIV, Israel & MELBOURNE, Australia (BUSINESS WIRE) Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the treatment of contact lens discomfort (CLD). The ECLIPTIC study examining Azura’s lead asset, AZR-MD-001, met its primary endpoints by showing statistically significant improvements in multiple measures of Meibomian gland secretion and patients’ ability to wear contact lenses as desired. Full data from the study will be submitted for presentation at an upcoming scientific meeting

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.